The speed at which semaglutide begins its weight-loss effects can vary from person to person. However, many people experience noticeable changes within a relatively short timeframe. Here’s a closer look at the timeline.

2021年2月10日 · Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to lifestyle intervention has not been confirmed.

2025年2月3日 · Semaglutide is used for weight loss, to lower blood sugar levels in type 2 diabetes, and to reduce the risk of major cardiovascular events and chronic kidney disease in certain adult patients.

Significant weight loss: Participants who received semaglutide 2.4 mg experienced a mean weight loss of 14.9% from baseline, compared to only 2.4% in the placebo group after 68 weeks.

2024年7月1日 · Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated clinically important weight loss effects in patients with type 2 diabetes. However, its effects on sustained weight loss in patients without diabetes remains unclear.

Semaglutide, the active ingredient in Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been approved by the Food and Drug Administration (FDA) for weight loss in adults with overweight or obesity.

Studies have shown that semaglutide can lead to significant weight loss in individuals with obesity or overweight, even in the absence of diabetes. Clinical trials have demonstrated that semaglutide treatment can result in substantial reductions in body weight compared to placebo [2].